Histone deacetylase inhibitors induce growth arrest and apoptosis of HTLV-1-infected T-cells via blockade of signaling by nuclear factor κB

Leukemia Research

Volumn 32, Issue 2, 2008, Pages 287-296

  Nishioka, Chie ^a   Ikezoe, Takayuki ^a   Yang, Jing ^a   Komatsu, Naoki ^a   Bandobashi, Kentaro ^a   Taniguchi, Ayuko ^a   Kuwayama, Yoshio ^a   Togitani, Kazuto ^a   Koeffler, H Phillip ^b   Taguchi, Hirokuni ^a  

^a KOCHI UNIVERSITY   (Japan)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apoptosis; ATL; Histone deacetylase inhibitor; Nuclear factor B

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; PANOBINOSTAT; PROTEIN SUBUNIT; VORINOSTAT;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DNA BINDING; DRUG EFFECT; DRUG INHIBITION; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS INFECTION; PRIORITY JOURNAL; T LYMPHOCYTE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZAMIDES; BLOTTING, WESTERN; CELL LINE; CELL PROLIFERATION; DELTARETROVIRUS INFECTIONS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME INHIBITORS; FLOW CYTOMETRY; HISTONE DEACETYLASES; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; HYDROXAMIC ACIDS; IMMUNOHISTOCHEMISTRY; LEUKEMIA-LYMPHOMA, ADULT T-CELL; NF-KAPPA B; PYRIDINES; SIGNAL TRANSDUCTION;

EID: 38949172381     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.05.026     Document Type: Article

References (24)

1. Hinuma Y., Nagata K., Hanaoka M., Nakai M., Matsumoto T., Kinoshita K.I., et al. Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci USA 78 (1981) 6476-6480
2. Yoshida M., Miyoshi I., and Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci USA 79 (1982) 2031-2035
3. Taguchi H., Kinoshita K.I., Takatsuki K., Tomonaga M., Araki K., Arima N., et al. An intensive chemotherapy of adult T-cell leukemia/lymphoma: CHOP followed by etoposide, vindesine, ranimustine, and mitoxantrone with granulocyte colony-stimulating factor support. J Acquir Immune Defic Syndr Hum Retrovirol 12 (1996) 182-186
4. Yamada Y., Tomonaga M., Fukuda H., Hanada S., Utsunomiya A., Tara M., et al. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol 113 (2001) 375-382
5. Mori N., Yamada Y., Ikeda S., Yamasaki Y., Tsukasaki K., Tanaka Y., et al. Bay 11-7082 inhibits transcription factor NF-kappaB and induces apoptosis of HTLV-1-infected T-cell lines and primary adult T-cell leukemia cells. Blood 100 (2002) 1828-1834
6. Okudaira T., Tomita M., Uchihara J.N., Matsuda T., Ishikawa C., Kawakami H., et al. NIK-333 inhibits growth of human T-cell leukemia virus type I-infected T-cell lines and adult T-cell leukemia cells in association with blockade of nuclear factor-kappaB signal pathway. Mol Cancer Ther 5 (2006) 704-712
7. Mori N., Fujii M., Cheng G., Ikeda S., Yamasaki Y., Yamada Y., et al. Human T-cell leukemia virus type I tax protein induces the expression of anti-apoptotic gene Bcl-xL in human T-cells through nuclear factor-kappaB and c-AMP responsive element binding protein pathways. Virus Genes 22 (2001) 279-287
8. Minucci S., and Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6 (2006) 38-51
9. Sakajiri S., Kumagai T., Kawamata N., Saitoh T., Said J.W., and Koeffler H.P. Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. Exp Hematol 33 (2005) 53-61
10. Hu J., and Colburn N.H. Histone deacetylase inhibition down-regulates cyclin D1 transcription by inhibiting nuclear factor-kappaB/p65 DNA binding. Mol Cancer Res 3 (2005) 100-109
11. Miyoshi I., Kubonishi I., Yoshimoto S., and Shiraishi Y. A T-cell line derived from normal human cord leukocytes by co-culturing with human leukemic T-cells. Gann 72 (1981) 978-981
12. Ikezoe T., Chen S.S., Heber D., Taguchi H., and Koeffler H.P. Baicalin is a major component of PC-SPES which inhibits the proliferation of human cancer cells via apoptosis and cell cycle arrest. Prostate 49 (2001) 285-292
13. Ikezoe T., Yang Y., Heber D., Taguchi H., and Koeffler H.P. PC-SPES: potent inhibitor of nuclear factor-kappa B rescues mice from lipopolysaccharide-induced septic shock. Mol Pharmacol 64 (2003) 1521-1529
14. Schimmer A.D., Dalili S., Batey R.A., and Riedl S.J. Targeting XIAP for the treatment of malignancy. Cell Death Differ 13 (2006) 179-188
15. Ikezoe T., Yang Y., Bandobashi K., Saito T., Takemoto S., Machida H., et al. Oridonin, a diterpenoid purified from Rabdosia rubescens, inhibits the proliferation of cells from lymphoid malignancies in association with blockade of the NF-kappa B signal pathways. Mol Cancer Ther 4 (2005) 578-586
16. Satou Y., Nosaka K., Koya Y., Yasunaga J.I., Toyokuni S., and Matsuoka M. Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro. Leukemia 18 (2004) 1357-1363
17. Lucas D.M., Davis M.E., Parthun M.R., Mone A.P., Kitada S., Cunningham K.D., et al. The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells. Leukemia 18 (2004) 1207-1214
18. Maggio S.C., Rosato R.R., Kramer L.B., Dai Y., Rahmani M., Paik D.S., et al. The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells. Cancer Res 64 (2004) 2590-2600
19. Rosato R.R., Maggio S.C., Almenara J.A., Payne S.G., Atadja P., Spiegel S., et al. The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide. Mol Pharmacol 69 (2006) 216-225
20. Djavaheri-Mergny M., Javelaud D., Wietzerbin J., and Besancon F. NF-kappaB activation prevents apoptotic oxidative stress via an increase of both thioredoxin and MnSOD levels in TNFalpha-treated Ewing sarcoma cells. FEBS Lett 578 (2004) 111-115
21. Takada Y., Gillenwater A., Ichikawa H., and Aggawal B.B. Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation. J Biol Chem 281 (2006) 5612-5622
22. Leoni F., Zaliani A., Bertolini G., Porro G., Pagani P., Pozzi P., et al. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc Natl Acad Sci USA 99 (2002) 2995-3000
23. Mishra N., Reilly C.M., Brown D.R., Ruiz P., and Gilkeson G.S. Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J Clin Invest 111 (2002) 539-552
24. Reddy P., Maeda Y., Hotary K., Liu C., Reznikov L.L., Dinarello C.A., et al. Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc Natl Acad Sci USA 101 (2004) 3921-3926